Interaction of Exogenous Butyrylcholinesterase with β-Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain

doi:10.2174/1567205018666210827122704

摘要

背景：在阿尔茨海默病 (AD) 和淀粉样蛋白模型（如 5XFAD 小鼠）中，丁酰胆碱酯酶 (BChE) 与 β-淀粉样蛋白 (Aβ) 斑块相关，并具有独特的生化特征，使其与神经元中发现的不同。有人提出与 Aβ 斑块相关的 BChE 可能参与该结构的成熟，从而参与疾病进展。目的：目前尚不清楚与 Aβ 斑块结合的 BChE 是否由于不同的一级结构或由于该酶与 Aβ 斑块的关联而改变了生化特性。此外，这种 BChE 的来源和结合机制仍然未知。方法：将来自 5XFAD/BChE-KO 小鼠的脑组织切片与外源 BChE 一起孵育，并对该酶的活性进行染色。已努力确定 BChE 或 Aβ 的哪个区域可能参与这种关联。结果：我们发现 5XFAD/BChE-KO 脑组织与外源性 BChE 的孵育导致这种酶与 Aβ 斑块和神经元相关。与神经元 BChE 相比，与 Aβ 斑块结合的 BChE 具有与 AD 中所见相似的生化特性。 BChE 的突变和阻断 Aβ 表型的努力未能阻止这种关联。结论：BChE 与 Aβ 斑块的关联以及由此产生的生化变化表明，当 BChE 与 Aβ 斑块而非神经元结合时，可能会发生构象变化。 5XFAD/BChE-KO 模型非常适合探索 BChE 与 Aβ 斑块的结合机制以及 BChE 参与 AD 发病机制。

关键词: 丁酰胆碱酯酶，β淀粉样蛋白斑块，5XFAD，神经变性，阿尔茨海默病，卡尔诺夫斯基根组织化学。

« Previous Next »

[1] 
Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell  2019; 179(2): 312-39.
[http://dx.doi.org/10.1016/j.cell.2019.09.001] [PMID: 31564456] 
[2] 
Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement  2012; 8(1): 1-13.
[http://dx.doi.org/10.1016/j.jalz.2011.10.007] [PMID: 22265587] 
[3] 
Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet  1976; 2(8000): 1403.
[http://dx.doi.org/10.1016/S0140-6736(76)91936-X] [PMID: 63862] 
[4] 
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science  1982; 215(4537): 1237-9.
[http://dx.doi.org/10.1126/science.7058341] [PMID: 7058341] 
[5] 
Friede RL. Enzyme histochemical studies of senile plaques. J Neuropathol Exp Neurol  1965; 24(3): 477-91.
[http://dx.doi.org/10.1097/00005072-196507000-00008] 
[6] 
Geula C, Mesulam M. Special properties of cholinesterases in the cerebral cortex of Alzheimer’s disease. Brain Res  1989; 498(1): 185-9.
[http://dx.doi.org/10.1016/0006-8993(89)90419-8] [PMID: 2790472] 
[7] 
Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord  1995; 9(2): 23-8.
[http://dx.doi.org/10.1097/00002093-199501002-00005] [PMID: 8534419] 
[8] 
Mesulam MM, Geula C, Morán MA. Anatomy of cholinesterase inhibition in Alzheimer’s disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol  1987; 22(6): 683-91.
[http://dx.doi.org/10.1002/ana.410220603] [PMID: 3435078] 
[9] 
Mesulam MM, Asuncion Morán M. Cholinesterases within neurofibrillary tangles related to age and Alzheimer’s disease. Ann Neurol  1987; 22(2): 223-8.
[http://dx.doi.org/10.1002/ana.410220206] [PMID: 3662453] 
[10] 
Wright CI, Geula C, Mesulam MM. Protease inhibitors and indolamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer’s disease. Ann N Y Acad Sci  1993; 695: 65-8.
[http://dx.doi.org/10.1111/j.1749-6632.1993.tb23029.x] [PMID: 8239315] 
[11] 
Darvesh S, Reid GA, Martin E. Biochemical and histochemical comparison of cholinesterases in normal and Alzheimer brain tissues. Curr Alzheimer Res  2010; 7(5): 386-400.
[http://dx.doi.org/10.2174/156720510791383868] [PMID: 19939227] 
[12] 
Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology  2006; 66(12): 1837-44.
[http://dx.doi.org/10.1212/01.wnl.0000219668.47116.e6] [PMID: 16801647] 
[13] 
Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA  2015; 313(19): 1924-38.
[http://dx.doi.org/10.1001/jama.2015.4668] [PMID: 25988462] 
[14] 
Macdonald IR, Maxwell SP, Reid GA, Cash MK, DeBay DR, Darvesh S. Quantification of butyrylcholinesterase activity as a sensitive and specific biomarker of Alzheimer’s disease. J Alzheimers Dis  2017; 58(2): 491-505.
[http://dx.doi.org/10.3233/JAD-170164] [PMID: 28453492] 
[15] 
Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol  1994; 36(5): 722-7.
[http://dx.doi.org/10.1002/ana.410360506] [PMID: 7979218] 
[16] 
Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol  1997; 42(6): 909-18.
[http://dx.doi.org/10.1002/ana.410420613] [PMID: 9403484] 
[17] 
Reid GA, Darvesh S. Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model. Neuroscience  2015; 298: 424-35.
[http://dx.doi.org/10.1016/j.neuroscience.2015.04.039] [PMID: 25931333] 
[18] 
Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci  2006; 26(40): 10129-40.
[http://dx.doi.org/10.1523/JNEUROSCI.1202-06.2006] [PMID: 17021169] 
[19] 
Li B, Duysen EG, Saunders TL, Lockridge O. Production of the butyrylcholinesterase knockout mouse. J Mol Neurosci  2006; 30(1-2): 193-5.
[http://dx.doi.org/10.1385/JMN:30:1:193] [PMID: 17192674] 
[20] 
Darvesh S, Reid GA. Reduced fibrillar β-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model. Chem Biol Interact  2016; 259(Pt B): 307-12.
[http://dx.doi.org/10.1016/j.cbi.2016.04.022] 
[21] 
Karnovsky MJ, Roots L. “Direct-coloring” thiocholine method for cholinesterases. J Histochem Cytochem  1964; 12: 219-21.
[http://dx.doi.org/10.1177/12.3.219] [PMID: 14187330] 
[22] 
Silver A. The biology of cholinesterases. North-Holland Pub. Co. 1974.
[23] 
Reid GA, Chilukuri N, Darvesh S. Butyrylcholinesterase and the cholinergic system. Neuroscience  2013; 234: 53-68.
[http://dx.doi.org/10.1016/j.neuroscience.2012.12.054] [PMID: 23305761] 
[24] 
Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol  1978; 4(4): 273-7.
[http://dx.doi.org/10.1111/j.1365-2990.1978.tb00545.x] [PMID: 703927] 
[25] 
Ramanan VK, Risacher SL, Nho K, et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol Psychiatry  2014; 19(3): 351-7.
[http://dx.doi.org/10.1038/mp.2013.19] [PMID: 23419831] 
[26] 
van Groen T, Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Brain Res Rev  2005; 48(2): 370-8.
[http://dx.doi.org/10.1016/j.brainresrev.2004.12.026] [PMID: 15850676] 
[27] 
Darvesh S, Cash MK, Reid GA, Martin E, Mitnitski A, Geula C. Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol  2012; 71(1): 2-14.
[http://dx.doi.org/10.1097/NEN.0b013e31823cc7a6] [PMID: 22157615] 
[28] 
Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA  2006; 103(23): 8628-33.
[http://dx.doi.org/10.1073/pnas.0602922103] [PMID: 16731619] 
[29] 
Podoly E, Bruck T, Diamant S, et al. Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro. Neurodegener Dis  2008; 5(3-4): 232-6.
[http://dx.doi.org/10.1159/000113711] [PMID: 18322399] 
[30] 
Kumar R, Nordberg A, Darreh-Shori T. Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs. Brain  2016; 139(Pt 1): 174-92.
[http://dx.doi.org/10.1093/brain/awv318] [PMID: 26525916] 
[31] 
Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer’s disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol  1993; 34(3): 373-84.
[http://dx.doi.org/10.1002/ana.410340312] [PMID: 8363355] 
[32] 
Ming LJ, Epperson JD. Metal binding and structure-activity relationship of the metalloantibiotic peptide bacitracin. J Inorg Biochem  2002; 91(1): 46-58.
[http://dx.doi.org/10.1016/S0162-0134(02)00464-6] [PMID: 12121761] 
[33] 
Mäkinen KK. Inhibition by bacitracin of some hydrolytic enzymes. Int J Protein Res  1972; 4(1): 21-8.
[http://dx.doi.org/10.1111/j.1399-3011.1972.tb03394.x] [PMID: 4552683] 
[34] 
Josviak ND, Batistela MS, Souza RKM, et al. Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer’s disease and dementia with Lewy bodies? Int J Neurosci  2017; 127(12): 1082-6.
[http://dx.doi.org/10.1080/00207454.2017.1329203] [PMID: 28504037] 
[35] 
Podoly E, Shalev DE, Shenhar-Tsarfaty S, et al. The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem  2009; 284(25): 17170-9.
[http://dx.doi.org/10.1074/jbc.M109.004952] [PMID: 19383604] 
[36] 
Blong RM, Bedows E, Lockridge O. Tetramerization domain of human butyrylcholinesterase is at the C-terminus. Biochem J  1997; 327(Pt 3): 747-57.
[37] 
Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet  1992; 50(5): 1086-103.
[PMID: 1570838] 
[38] 
Podoly E, Hanin G, Soreq H. Alanine-to-threonine substitutions and amyloid diseases: butyrylcholinesterase as a case study. Chem Biol Interact  2010; 187(1-3): 64-71.
[http://dx.doi.org/10.1016/j.cbi.2010.01.003] [PMID: 20060816] 
[39] 
Masson P, Xie W, Froment MT, et al. Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta  1999; 1433(1-2): 281-93.
[http://dx.doi.org/10.1016/S0167-4838(99)00115-6] [PMID: 10446378] 
[40] 
Masson P, Legrand P, Bartels CF, Froment MT, Schopfer LM, Lockridge O. Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human butyrylcholinesterase. Biochemistry  1997; 36(8): 2266-77.
[http://dx.doi.org/10.1021/bi962484a] [PMID: 9047329] 
[41] 
Levitsky V, Xie W, Froment MT, Lockridge O, Masson P. Polyol-induced activation by excess substrate of the D70G butyrylcholinesterase mutant. Biochim Biophys Acta  1999; 1429(2): 422-30.
[http://dx.doi.org/10.1016/S0167-4838(98)00253-2] [PMID: 9989227] 
[42] 
Masson P, Nachon F, Bartels CF, et al. High activity of human butyrylcholinesterase at low pH in the presence of excess butyrylthiocholine. Eur J Biochem  2003; 270(2): 315-24.
[http://dx.doi.org/10.1046/j.1432-1033.2003.03388.x] [PMID: 12605682] 
[43] 
Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther  2015; 148: 34-46.
[http://dx.doi.org/10.1016/j.pharmthera.2014.11.011] [PMID: 25448037] 
[44] 
Arendt T, Brückner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development--a study of molecular forms. Neurochem Int  1992; 21(3): 381-96.
[http://dx.doi.org/10.1016/0197-0186(92)90189-X] [PMID: 1303164] 
[45] 
Atack JR, Perry EK, Bonham JR, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid. J Neurochem  1987; 48(6): 1845-50.
[http://dx.doi.org/10.1111/j.1471-4159.1987.tb05746.x] [PMID: 3572402] 
[46] 
Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol  2009; 47(4): 289-99.
[PMID: 20054780] 
[47] 
Kalaria RN, Kroon SN, Grahovac I, Perry G. Acetylcholinesterase and its association with heparan sulphate proteoglycans in cortical amyloid deposits of Alzheimer’s disease. Neuroscience  1992; 51(1): 177-84.
[http://dx.doi.org/10.1016/0306-4522(92)90482-H] [PMID: 1465181] 
[48] 
Kolarich D, Weber A, Pabst M, et al. Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics  2008; 8(2): 254-63.
[http://dx.doi.org/10.1002/pmic.200700720] [PMID: 18203274] 
[49] 
Furukawa-Hibi Y, Alkam T, Nitta A, et al. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behav Brain Res  2011; 225(1): 222-9.
[http://dx.doi.org/10.1016/j.bbr.2011.07.035] [PMID: 21820013] 
[50] 
Kamal MA, Shakil S, Nawaz MS, et al. Inhibition of butyrylcholinesterase with fluorobenzylcymserine, an experimental Alzheimer’s drug candidate: Validation of enzoinformatics results by classical and innovative enzyme kinetic analyses. CNS Neurol Disord Drug Targets  2017; 16(7): 820-7.
[http://dx.doi.org/10.2174/1871527316666170207160606] [PMID: 28176640] 

Rights & Permissions Print Cite

Article Metrics

10

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1567205018666210827122704	Print ISSN 1567-2050
Publisher Name Bentham Science Publisher	Online ISSN 1875-5828

当代阿耳茨海默病研究

外源性丁酰胆碱酯酶与 5XFAD/丁酰胆碱酯酶敲除小鼠脑中 β-淀粉样蛋白斑块的相互作用

摘要

当代阿耳茨海默病研究

外源性丁酰胆碱酯酶与 5XFAD/丁酰胆碱酯酶敲除小鼠脑中 β-淀粉样蛋白斑块的相互作用

摘要 Play Pause

Related Journals

Related Books

摘要